Our study is register based, so any results need to be taken with a grain of salt and we shouldnt talk about causality, Lhteenvuo explained
On June 12, 2023, Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that new findings for efinopegdutide (MK-6024), an investigational GLP-1/glucagon receptor co-agonist, have been accepted for oral presentation at the European Association for the Study of the Liver (EASL) Annual Congress from June 21-24
This represents a significant convenience advantage over daily injection options like liraglutide (Saxenda)
Thats about 30% off, or about $600 in savings
At Orthobiologics Associates, we are dedicated to providing personalized care plans that focus on healing, rehabilitation, and lifestyle improvements
Ahlrichs, B